Lilly’s orforglipron beats oral semaglutide in diabetes trial
In the ACHIEVE-3 trial of 1,698 adults on metformin, Eli Lilly’s oral agent orforglipron produced larger HbA1c reductions (2.2% vs 1.4%) and greater weight loss (9.2% vs 5.3%) than oral semaglutide. Orforglipron can be taken with meals, improving dosing convenience, but gastrointestinal adverse events were more frequent and about 10% discontinued treatment. Diabetes specialists Michael Nauck and Michael Horowitz urge cautious interpretation and individualized treatment choices.
Why it mattersACHIEVE-3 results show stronger glycemic and weight benefits versus oral semaglutide in 1,698 patients.
People Mentioned
Michael NauckMichael HorowitzKyle Umipig